首页> 外文期刊>Interventional cardiology. >Transcatheter aortic and mitral valve interventions: update 2010
【24h】

Transcatheter aortic and mitral valve interventions: update 2010

机译:经导管主动脉和二尖瓣介入:2010年更新

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In recent years, the cardiovascular community has witnessed the advent of new, transcatheter-based beating-heart approaches to valvular heart disease. Since the mid-1980s, when balloon valvuloplasty of stenosed aortic valves and percutaneous commissurotomy in mitral stenosis were introduced into clinical practice, interventional valve therapy has seen a tremendous upsurge. Today, transcatheter aortic valve implantation has become a viable treatment alternative for selective cases at specialized centers. While transcatheter aortic valve implantation is currently restricted to high-risk patients and surgical aortic valve replacement remains the reference treatment, broader clinical application can be anticipated for the future. Nonsurgical intervention for treatment of mitral regurgitation is a second field of intense investigation. The growing incidence of congestive heart failure in western societies has created an unmet clinical need for less invasive treatment strategies for patients with functional or organic mitral regurgitation. This article summarizes the current state of transcatheter aortic and mitral valve interventions and discusses future perspectives.
机译:近年来,心血管病界见证了基于经导管的新型心脏跳动方法对瓣膜性心脏病的出现。自1980年代中期以来,当将狭窄的主动脉瓣膜球囊成形术和二尖瓣狭窄的经皮皮肤合缝术引入临床实践时,介入性瓣膜治疗已出现了巨大的兴起。如今,经导管主动脉瓣植入已成为专门中心选择性病例的可行治疗选择。尽管目前经导管主动脉瓣植入仅限于高危患者,而外科主动脉瓣置换仍是参考治疗,但未来可望有更广泛的临床应用。非手术干预治疗二尖瓣反流是第二个深入研究的领域。在西方社会,充血性心力衰竭的发病率不断增长,已经为功能性或器质性二尖瓣反流患者的微创治疗策略带来了尚未满足的临床需求。本文总结了经导管主动脉和二尖瓣介入治疗的现状,并讨论了未来的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号